心筋梗塞治療薬の世界市場2016-2020...市場調査レポートについてご紹介

【英文タイトル】Global Myocardial Infarction Drugs Market 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Key buying criteria

PART 05: Disease overview
• Types of myocardial infarction
• Pathophysiology
• Risk factors
• Diagnosis
• Management

PART 06: Epidemiology and economic burden
• Burden of disease

PART 07: Pipeline analysis
• Canakinumab
• MyoCell
• MultiStem therapy
• CLBS10
• Prochymal
• Revascor
• CicloMulsion
• PP-099
• NP202
• CAP-1002
• Revacept
• CSL112

PART 08: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 09: Market segmentation by drug class
• Beta blockers
• ACE inhibitors
• ARBs
• Vasodilators
• Antithrombotic agents
• Thrombolytics
• Glycoprotein IIb/IIIa inhibitors
• Anti-dyslipidemic drugs
• Calcium channel blockers
• Analgesics

PART 10: Market segmentation by EKG appearance
• NSTEMI
• STEMI

PART 11: Market segmentation by type
• Brand-name drugs
• Generic drugs

PART 12: Geographical segmentation
• Global myocardial infarction drugs market segmentation by geography 2015-2020
• Myocardial infarction drugs market in Americas
• Myocardial infarction drugs market in EMEA
• Myocardial infarction drugs market in APAC

PART 13: Market drivers
• Increase in older population
• Sedentary lifestyle
• Rise in obesity
• High prevalence of chronic conditions

PART 14: Impact of drivers

PART 15: Market challenges
• Delayed diagnosis
• Alternative therapies
• Extensive use of generics

PART 16: Impact of drivers and challenges

PART 17: Market trends
• Growing awareness of disease
• Strategic alliances
• Increased R&D
• Prevalent use of stent grafts

PART 18: Vendor landscape
• Competitive scenario
• AstraZeneca
• Bayer HealthCare
• Eli Lilly
• Novartis
• Pfizer
• Sanofi
• Other prominent vendors

PART 19: Appendix
• List of abbreviations

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for myocardial infarction drugs
Exhibit 03: Pathophysiology of myocardial infarction
Exhibit 04: Risk factors of myocardial infarction
Exhibit 05: Diagnostic techniques for myocardial infarction
Exhibit 06: Treatment options for myocardial infarction
Exhibit 07: Projected prevalence of CVDs in US
Exhibit 08: Projected economic burden for CVDs in US
Exhibit 09: Pipeline portfolio: Myocardial infarction
Exhibit 10: Global myocardial infarction drugs market 2015-2020 ($ billions)
Exhibit 11: Five forces analysis
Exhibit 12: Global myocardial infarction drugs market segmentation by EKG appearance 2015
Exhibit 13: Global myocardial infarction drugs market segmentation by type 2015
Exhibit 14: Global myocardial infarction drugs market segmentation by geography 2015
Exhibit 15: Myocardial infarction drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 16: Myocardial infarction drugs market in Americas 2015-2020 ($ billions)
Exhibit 17: Myocardial infarction drugs market in EMEA 2015-2020 ($ billions)
Exhibit 18: Myocardial infarction drugs market in APAC 2015-2020 ($ billions)
Exhibit 19: Global myocardial infarction drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 20: Impact of drivers
Exhibit 21: Impact of drivers and challenges
Exhibit 22: AstraZeneca: Business segmentation by revenue 2014
Exhibit 23: AstraZeneca: Cardiovascular and metabolic diseases segment by revenue 2014
Exhibit 24: AstraZeneca: YoY revenue and growth rate of Crestor 2012-2014 ($ billions)
Exhibit 25: AstraZeneca: YoY revenue and growth rate of Seloken/Toprol 2012-2014 ($ millions)
Exhibit 26: AstraZeneca: YoY revenue and growth rate of Atacand 2012-2014 ($ millions)
Exhibit 27: AstraZeneca: YoY revenue and growth rate of Brilinta/Brilique 2012-2014 ($ millions)
Exhibit 28: AstraZeneca: Key takeaways
Exhibit 29: Bayer HealthCare: YoY revenue and growth rate of Xarelto 2012-2014 ($ millions)
Exhibit 30: Bayer HealthCare: YoY revenue and growth rate of Adalat 2012-2014 ($ millions)
Exhibit 31: Bayer HealthCare: Key takeaways
Exhibit 32: Eli Lilly: YoY revenue and growth rate of Effient (global) 2012-2015 ($ millions)
Exhibit 33: Eli Lilly: YoY revenue and growth rate of Effient in US 2012-2015 ($ millions)
Exhibit 34: Eli Lilly: YoY revenue and growth rate of Effient in rest of world 2012-2015 ($ millions)
Exhibit 35: Eli Lilly: Key takeaways
Exhibit 36: Novartis: YoY revenue and growth rate of Diovan 2012-2015 ($ billions)
Exhibit 37: Novartis: YoY revenue and growth rate of Exforge 2012-2015 ($ billions)
Exhibit 38: Novartis: Key takeaways
Exhibit 39: Pfizer: YoY revenue and growth rate of Lipitor 2012-2014 ($ billions)
Exhibit 40: Pfizer: YoY revenue and growth rate of Norvasc 2012-2014 ($ billions)
Exhibit 41: Pfizer: YoY revenue and growth rate of Fragmin 2012-2014 ($ millions)
Exhibit 42: Pfizer: YoY revenue and growth rate of Caduet 2012-2014 ($ millions)
Exhibit 43: Pfizer: Key takeaways
Exhibit 44: Sanofi: YoY revenue and growth rate of Plavix 2012-2014 ($ billions)
Exhibit 45: Sanofi: YoY revenue and growth rate of Lovenox 2012-2014 ($ billions)
Exhibit 46: Sanofi: Key takeaways


【レポート販売概要】

■ タイトル:心筋梗塞治療薬の世界市場2016-2020
■ 英文:Global Myocardial Infarction Drugs Market 2016-2020
■ 発行日:2016年3月8日
■ 調査会社:Technavio
■ 商品コード:IRTNTR8952
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。